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Abstract
Resveratrol (RSV) is a natural nonflavonoid polyphenol compound containing a stilbene 
structure similar to that of estrogen diethylstilbestrol. It is a fat-soluble compound exist-
ing in cis-, trans-, and piceid isomeric forms, isolated for the first time in 1940 from a plant 
used in traditional Chinese and Japanese medicine. Although initially used for cancer 
therapy, it has shown beneficial effects against most cardiovascular and cerebrovascular 
diseases. Its beneficial effects are mainly related to its antioxidant properties. Here, we 
review the metabolism and the ability of RSV to modulate redox signaling and to interact 
with multiple molecular targets of different intracellular pathways exerting protective 
effects against cardio-cerebrovascular diseases and metabolic disorders such as diabetes, 
reporting evidence in animal models and its efficacy and toxicity in humans. The aim of 
this chapter is to highlight the mechanisms, the biology, and the potential use of resvera-
trol to prevent, protect and aid cardio- and cerebrovascular diseases.
Keywords: resveratrol, cardiovascular diseases, cerebrovascular diseases, molecular 
mechanisms, clinical effects, nitric oxide, oxidative stress
1. Introduction
Both in the scientific world and in the public opinion, a particular attention is paid to car-
diovascular diseases since they represent the first cause of mortality in the Western world. 
The major risk factors are represented by different factors such as hyperlipidemia, arterial 
hypertension, diabetes and obesity, and the common anatomopathological basis is atheroscle-
rosis. Since the early 50s of the last century, the pioneering studies of the American scientist 
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Ancel Keys have highlighted the enormous potential of proper nutrition in the prevention 
of cardiovascular diseases (CVDs). Since then, the interest in food science has been growing 
and was corroborated by the discovery of new associations between healthy nutrition and 
protection against other cardiovascular diseases, such as diabetes, hypertension, atheroscle-
rosis and myocardial infarction. A clear and concise testimony of the work of the American 
scientist provides it in a recent article that M. Mancini and J. Stamler, certainly two scholars 
who in their respective countries, Italy and the United States, have contributed most to spread 
and develop Keys’ theorems [1]. The legacy of Keys is fundamentally contained in the seven 
countries study (SCS), which he initiated and coordinated, in which it has unequivocally 
demonstrated through the study of different populations that a high intake of saturated fats 
causes an increase in blood cholesterol and risk mortality for CVDs and that the level of blood 
cholesterol correlates with the risk of CVDs. Years later, Keys’ insights, which were validated 
by epidemiological population studies, are now validated and investigated at the cellular and 
molecular level.
In the context of the recognized benefits deriving from “healthy eating,” the chemical com-
ponents that are largely responsible for the protective effects of the diet are gradually being 
highlighted. The importance of diet in the prevention of vascular diseases and dysfunction is 
highlighted by the observation that the incidence of certain diseases varies from country to 
country, where there are different eating habits. In vitro and in vivo studies have shown that 
some components of the diet, including vitamin E, vitamin C, retinoic acid, carotenoids such 
as lycopene (a powerful antioxidant in tomato) and polyphenols show a protective effect on 
the onset of CVDs [2].
On this regard, polyphenols are compounds that own one or more aromatic rings, with one 
or more hydroxyl groups and are generally classified as phenolic acids, flavonoids, stilbenes, 
coumarin, and tannins. Polyphenols are products of the secondary metabolism of plants, 
whose function is to protect the plant from the pathogenic attacks of parasites and also con-
tribute to giving color to the plants [3]. Polyphenols have different structures, but all have 
aromatic rings, with one or more hydroxyl substituents; due to their structure, they are able 
to chelate metal ions and have the activity of scavengers of free radicals; they are also able to 
inhibit inflammation and platelet aggregation, thus exerting a protective action on the vascular 
system. Due to the acid character of the hydroxyl groups and the nucleophilic properties of the 
phenolic rings, the flavonoids are highly reactive and appear to have antiviral, antibacterial, 
immunostimulatory, anti-ischemic, antineoplastic, anti-inflammatory and gastroprotective 
properties. Flavonoids inhibit the activity of many enzymes including lipoxygenase, cyclo-
oxygenase, monooxygenase, xanthine oxidase, NADPH-oxidase, phospholipase A2, some 
protein kinases and transcription factors such as NF-kB [4].
Among the flavonoids, resveratrol (3,5,4′-trihydroxystilbene) has attracted considerable 
attention from the scientific community. It belongs to the stilbenes family. The stilbenes 
(C6-C2-C6) are low molecular weight phenolic compounds, characterized by the presence 
of two aromatic rings joined by an ethane or an ethylene bridge. Resveratrol (RSV) (trans-
3,4,5′-trihydroxystilbene) is a natural phytoalexin synthesized in response to fungal attacks, 
or to abiotic agents such as exposure to ultraviolet rays. Present in the peel of grapes and in 
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red wine, RSV has a wide variety of pharmacological properties [5]. Since its first isolation 
in 1940 by Takaoka, RSV has been associated with many properties [6]. Above all, the detec-
tion of RSV in wine has greatly contributed to finding the cardioprotective effects of this 
compound. This is testified by the so-called “French paradox,” in which despite equal CVD 
risk factors, French population has a lower mortality rate compared to western countries [7]. 
This discovery about 25 years ago gave rise to an increasingly compelling urge to research 
all the mechanisms lying behind RSV and its beneficial effects [8]. This, unfortunately, gave 
also birth to a “red wine/RSV dogma,” hence the concept that red wine benefits are due to 
its content in highly bioactive RSV. This concept might seem logic at first, as red wine is the 
main RSV dietary source; however, RSV content in wine is greatly variable and usually low, 
so its effects are mostly unpredictable and so its biological benefits are rather overestimated 
[7, 9–11]. Besides this noteworthy mention, consumption of red wine has been associated 
with beneficial effects on both the healthy and in patients with the previous acute coronary 
syndrome in terms of reduction in oxidative stress and endothelial function improvement 
[12, 13]. Other studies have shown that moderate consumption of red wine on man produces 
a reduction in risk factors for atherosclerosis. In red wine consumers, in fact, a reduction in 
platelet aggregation leads to an increase in plasma levels of HDL-cholesterol (HDL, high-
density lipoprotein, responsible for the disposal of excess cholesterol in the peripheral tissues) 
and to a more low oxidation of low-density lipoprotein (LDL); these events are associated 
with a minor formation of atherosclerotic plaques in blood vessels and, therefore, a reduction 
in cardiovascular events, which makes RSV a cardioprotective agent [14, 15]. RSV, like many 
phytoalexins, has many biological activities—inhibition of lipid peroxidation and platelet 
aggregation, and alteration of lipid metabolism—possesses anti-inflammatory activity, is an 
inhibitor of the damage induced by free radicals and exerts an important vasorelaxant effects 
in different vascular districts.
2. Resveratrol and cardiovascular diseases: molecular mechanisms
A human takes with the diet small amounts of stilbenes, but one of the most represented is 
RSV. It is absorbed more in the duodenum; studies conducted on mice, using labeled RSV, 
have detected, already after 3 h from the administration, the presence of this molecule in 
the brain, heart, lungs, spleen and testicles, and after 6 h the stay in the liver and kidneys. In 
plasma, however, its concentration is very low and of short half-life. Trans-RSV has several 
beneficial effects and can act at different levels such as cellular signals, enzymatic processes, 
apoptosis and gene expression [16, 17]. Being lipophilic, RSV binds preferentially to HDL, 
LDL and VLDL lipoproteins, protecting them from oxidation from ionic metals and remov-
ing copper ions from both LDL and arterial walls. It is transported in the bloodstream bound 
mainly to LDL, both as an intact molecule and as its metabolites: trans-RSV-3-O-glucuronide, 
cis-RSV-3-O-glucuronide and cis-RSV-3-O-glucoside [18]. It has been shown that about 75% 
of trans-RSV taken with red wine is absorbed by passive diffusion and only <1% is bioavail-
able in the liver and in the intestine. Despite its very low concentration and of short half-life 
after assumption, RSV exerts several beneficial effects in different CVDs (Figure 1).
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2.1. Atherosclerosis
Atherosclerosis is a chronic inflammation of the vascular wall that results in the development 
of plaques and subsequent stenosis of the arteries [19]. A number of cytokines are involved 
in atherosclerosis-related inflammation; these include tumor necrosis factor alpha (TNF-α), 
interleukin (IL)-6 and monocyte chemoattractant protein-1 (MCP-1). These factors induce the 
expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 
(VCAM-1) and E-selectin adhesion molecules and lipid homeostasis [20, 21]. Other important 
cytokines responsible for the cross-talk phenomenon that occurs between inflammatory cells 
and intrinsic factor wall cells are IL-1β and platelet-derived growth factor cross-reactive mate-
rial [19]. Inflammation associated with atherosclerosis is mediated via the nuclear factor κB 
(NF-κB) signaling pathway, implying that substances inhibiting or activating this factor exert 
an important role in atherogenesis [22].
RSV is able to interfere with the activation of NF-kB, a transcription factor that regulates the 
expression of various genes involved in inflammation, cell proliferation and carcinogenesis 
such as COX2 cyclooxygenase and nitric oxide synthase (iNOS). Nitric oxide synthase main-
tains high concentrations of nitric oxide molecule able to exert vasodilatory effects, to inhibit 
adhesion and platelet aggregation and to block the cell growth and migration. Recently, it 
has been shown that RSV is an activator of sirtuins [23]. The sirtuins are a class of NAD-
dependent deacetylases, implicated in the transcriptional modulation of the silencing of genes 
of the aging and cell survival processes. A large number of sirtuins appear to be involved 
in promoting longevity in mammals. RSV activates human sirtuin 1 (SIRT 1), a homolog of 
silencing information regulator 2 (SIR 2) of yeast [24]. SIRT 1 is involved in a multiplicity of 
cellular and metabolic events with a pivotal role in many of them. For example, it mobilizes 
fats from adipose tissue blocking the activity of peroxisome proliferator activated receptor-
gamma (PPAR-gamma) receptors through its interaction with the NCOR nuclear receptor 
corepressor. Furthermore, it represses the transcriptional activity of the nuclear factor NF-kB 
by deacetylating the p65 subunit. SIRT 1 also modulates mitochondrial cell metabolism thanks 
Figure 1. Schematic of molecular mechanisms of resveratrol in cardiovascular diseases.
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to the deacetylation performed on the PPAR-gamma receptor coactivator, PGC1 alpha and 
cell survival in stress conditions thanks to interaction with FOXO proteins. Moreover, it has 
been demonstrated that RSV is able to induce NOS-3 in direct and indirect manners through 
the 5′adenosine monophosphate-activated protein kinase (AMPK), SIRT1 and nuclear factor 
erythroid 2-related factor two pathways, thus modulating the vessels homeostasis [25].
In ApoE −/−/LDLR−/− mice, the lack of apolipoprotein E (ApoE) or LDL receptor (LDLR), and 
the over-expression of apolipoprotein B (ApoB) gene, leads to an increase in VLDL and LDL, 
contributing to the promotion of atherosclerosis [26]. In vivo studies in genetically hypercho-
lesterolemic mice (ApoE−/−/LDLR−/−) and treated with oral administration of RSV in associa-
tion with a high fat diet content have shown that the polyphenol suppresses the formation of 
atheroma in the aorta and reduces the laser-induced thrombosis in the carotid arteries [27], 
thus demonstrating the positive effect of RSV. An important antioxidant action of RSV is the 
inhibition of the oxidation of LDL; this inhibition is protective because the oxidative modi-
fication of LDL is considered a primary event in the pathogenesis of atherosclerosis. In fact, 
several studies have reported that oxidized LDL (ox-LDL) can stimulate platelet aggregation 
[28] and promote a procoagulant activity on the surface of human monocytes/macrophages, 
increasing the thromboplastin activity in the tissue [29]. Various enzymatic systems, present 
in endothelial cells and macrophages, are implicated in the oxidation of LDL. These systems 
include NADPH-oxidase, hypoxanthine/xanthine oxidase, myeloperoxidase (MPO) and the 
enzyme nitric oxide synthase (NOS) [30–32]. The products of these enzymes oxidize LDL, 
which alter endothelial cells, stimulate NADPH-oxidase, release pro-inflammatory cytokines 
and inhibit the endothelial enzyme nitric oxide synthase (eNOS) involved in the vasorelaxing 
activity [33]. RSV has been shown to act on these ROS scavenger enzymes by inhibiting the 
COX-2 cyclooxygenase and thus the expression of the scavenger receptor (SR-A) and induc-
ing the vasorelaxing activity of eNOS [34]. It is well known that vascular smooth muscle cells 
(VSMCs) contribute to the pathogenesis of atherosclerotic lesions since their migration and 
proliferation are critical events for the progressive thickening in the intimate and develop-
ment of atheroma in the vascular wall [35]. Several studies have shown that RSV can inhibit 
the proliferation of VSMCs [36, 37], induced by different mitogens such as serum, endothelin 
and PGDF. The antiproliferative effect of RSV is not mediated by the induction of apoptosis, 
but appears to be produced by the blockade of the G1-S transition of the cell cycle [38, 39] and 
of the synthesis of DNA [37]. These results suggest that RSV can selectively counteract the 
pathological proliferation of VSMCs in arterial walls in vivo and thus could exert an impor-
tant protective effect on the onset of atherosclerosis.
2.2. Hypertension
Hypertension is one of the most important risk factors for cardiovascular diseases, represent-
ing the main causes of death in developed countries. It involves from 30 to 45% of the general 
population, with a tendency to increase incidence from the age of 50 and with an increase in 
prevalence in the most disadvantaged social classes [40].
The endothelial dysfunction is a hallmark of hypertension and clearly contributes to the onset 
and progression of the disease. It is important to underline that several risk factors for cardiovas-
cular diseases can be effectively countered by a proper diet and by the intake of nutraceuticals.
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On this regard, it has been demonstrated that RSV increases the levels of the vasodilator NO, 
which protects against the high blood pressure levels and subsequent cardiac hypertrophy 
and decreases ET-1 and angiotensin II (AngII) concentrations, which are associated with 
higher hypertension [41, 42]. In several animal models of hypertension, chronic RSV admin-
istration reduces systemic blood pressure in different rat models of hypertension [42, 43], 
suggesting the important beneficial effects evoked by polyphenol. RSV has also been shown 
to prevent remodeling of the mesenteric artery wall of spontaneously hypertensive rats 
(SHR), which is also typically observed in hypertensive humans, and to limit the increase in 
compliance of SHR arteries [44].
In another animal model of metabolic syndrome, the increased systolic blood pressure and 
reduced aortic eNOS expression were significantly improved by long-term administration 
of RSV. In the visceral adipose tissue (VAT) of this rat type, RSV treatment lowered tumor 
necrosis factor-alpha (TNF-α) production and increased the concentration of adiponectin, 
which improved the inflammatory status [45]. The development of pulmonary hyperten-
sion is induced by the proliferation of pulmonary arterial smooth muscle cells, endothelial 
dysfunction, oxidative stress, and inflammation. In monocrotaline-treated rats, RSV attenu-
ated right ventricular systolic pressure, increased expression of endothelial NO synthase, 
decreased oxidative stress, and improved endothelial function in small pulmonary arteries. 
In addition, RSV was able to decrease expression of inflammatory cytokines, such as (TNF-α) 
and interleukin 6 (IL-6), and to limit leukocyte infiltration in the lung [46]. RSV also inhibited 
proliferation of pulmonary arterial smooth muscle cells. The increased level of NO induced 
by RSV is due to the augmentation of eNOS expression and activity [47]. It has been proposed 
that these effects involve SIRT1, which has been shown to directly deacetylate eNOS [48] 
leading to the improvement of nitric oxide production. It is well known that endothelial cells 
are responsible for the synthesis of ET-1, which is a strong vasoconstricting factor. RSV poten-
tially inhibits stress-induced ET-1 gene expression, ET-1 mRNA levels, and ET-1 promoter 
activity by interfering with the ERK 1/2 pathway improving endothelial function through the 
decrease of ET-1 levels [49].
2.3. Cardiac remodeling
Chronic cardiovascular disease, such as hypertension, heart failure, or myocardial infarction, 
induces remodeling of the heart [50]. The remodeling process is characterized by hyper-
trophy of myocytes, hyperplasia of fibroblasts and vascular smooth muscle cells, excessive 
collagen deposition, and conduction abnormalities. As described above, RSV is able to pre-
vent increased blood pressure in animal models; thus, it can protect the heart from struc-
tural remodeling (i.e., left ventricular hypertrophy, LVH) associated with pressure overload. 
Another antihypertrophic mechanism of RSV is via AMPK and its upstream kinase LKB1. 
AMPK not only reduces the hypertrophic response, but also delays the transition from car-
diac to heart failure [51]. In hypertensive patients and rats, oxidative stress and lipid peroxi-
dation products, such as 4-hydroxy-2-nonenal (4-HNE), are elevated [52]. 4-HNE produces 
an inhibitory effect on the LKB1/AMPK signaling pathway, with consequent induction of 
mTOR/p70S6 kinase-mediated protein synthesis and cardiac myocyte cell growth. RSV 
prevents the pro-hypertrophic effect of 4-HNE by the activation of AMPK [53]. Thus, RSV 
inhibits unnecessary protein synthesis and prevents remodeling of the heart [54]. RSV has 
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also effects on cell proliferation. Block of cell proliferation could also improve cardiac func-
tion. In cultured rat cardiac fibroblasts, RSV inhibited their proliferation and differentiation 
to the hypersecretory myofibroblast phenotype; these are two critical steps in cardiac collagen 
deposition. Another probable mechanism through which RSV can inhibit the proliferation 
of cultured rat cardiac fibroblasts is the activation of the NO-cGMP signaling pathway [55]. 
Since inflammation is a key initiator of fibrosis, the anti-inflammatory properties of RSV could 
be another contributory mechanism to the changes in cardiac remodeling. In mouse cardiac 
fibroblasts, RSV inhibited the high expression of PI3K/Akt/ERK-dependent interleukin-17, 
a pro-inflammatory cytokine, induced by high glucose levels; thus, RSV may decrease high 
glucose-mediated myocardial inflammation and remodeling [56].
2.4. Diabetes
The term diabetes does not indicate a single pathological entity but rather a clinical syndrome 
characterized by chronic hyperglycemia with alterations in the metabolism of carbohydrates, 
fats, and proteins, due to defects in secretion and/or insulin action [57]. The cause of diabetes 
continues to be unknown, although researchers’ attention is increasingly focused on a num-
ber of factors: the increase in obesity, the increase in the average age and life expectancy, a 
style of a more sedentary life, an increase in stress, and, above all, genetics. This disease is 
called a heterogeneous syndrome because it includes various clinical forms, of which the 
most frequent are type 1 or insulin-dependent diabetes mellitus (T1DM or IDDM) and type 
2 or noninsulin-dependent diabetes mellitus (T2DM or NIDDM). Type 1 diabetes (also called 
juvenile diabetes because it occurs generally in the first 30 years of life) is determined by 
an autoimmune destruction of the beta cells of the Isles of Langerhans, which results in a 
total absence of insulin and represents about 10% of diabetes cases [58, 59]. Type 2 diabetes, 
which represents approximately 90% of cases, occurs predominantly after 35–40 years of age 
with reduced insulin secretion associated with a resistance by the tissues to the action of the 
hormone itself. The onset, difficult to diagnose, is characterized by hyperglycemia and conse-
quent polyuria, polydipsia, and polyphagia. Obesity or overweight is another characteristic 
of individuals suffering from this pathology [60].
RSV also prevents or delays the onset of chronic age-associated diseases such as type II dia-
betes, improves insulin sensitivity, reduces blood glucose levels, and reduces high-fat-diet-
induced obesity in rodents [56].
In a recent study, it has been reported that the multiple aspects of the action of RSV on the 
mechanisms control glucose homeostasis [61]. Polyphenol plays a protective role on pancre-
atic islets by increasing the synthesis of antioxidant enzymes, such as superoxide dismutase, 
glutathione peroxidase, and glutathione-s-transferase, which counteract the action of free 
radicals [62]. The antiapoptotic power toward β-cells has emerged both in animal models 
with streptozotocin toxic damage and in the autoimmune insulin of type 1 diabetes mellitus, 
where the action of RSV manifests itself by reducing the expression of the chemokine receptor 
6 and inhibiting the migration of inflammatory cells into the pancreas [63, 64]. Furthermore, 
RSV modulates glycemic homeostasis at hepatic level, reducing the activity of the enzymes of 
gluconeogenesis and increasing, on the contrary, that of glycogen synthase [65]. At the muscle 
level, as well as the hepatic, the optimization of fatty acid metabolism and the reduction of 
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NF-kB and pro-inflammatory cytokines in the target organs are due to a direct action of the 
polyphenol, which induces a partial regeneration of β-cells and causes an increase in the 
plasma concentration of insulin [66]. In type 2 diabetes mellitus, RSV counteracts insulin 
resistance in rats fed with hyperlipemia diet and high in fructose as well as in those with 
genetically determined insulin resistance. In obese rats, in fact, the polyphenol contrasts the 
adipogenesis and reduces the macrophagic infiltrate in the adipose tissue, the main source 
of adiponectin, coresponsible for the appearance of insulin resistance [67, 68]. Furthermore, 
the polyphenol determines the reduction of the muscular and hepatic lipid content. These 
effects are due to the modulation of the action of two important intracellular regulators, a 
histone deacetylase (SIRT1) and an AMP-dependent kinase (AMPK), which control determi-
nant cellular functions such as intracellular energy metabolism, mitochondrial function, and 
apoptosis [69]. These data have also been confirmed in primates and obese men where chronic 
treatment with RSV seems to improve insulin sensitivity [70]. In conclusion, the pleiotropic 
action of RSV makes this polyphenol a possible additional natural resource in the treatment 
of the diabetic patient. Its beneficial effect manifests itself through the increase of insulin 
secretion, the reduction of insulin resistance, and the suppression of hepatic gluconeogenesis. 
Furthermore, the efficacy of RSV in mitigating the autoimmune destruction of β-pancreatic 
cells is particularly relevant from the clinical point of view because it could represent a sup-
port to the conventional treatment of the patient with type 1 diabetes mellitus.
3. Clinical trials on resveratrol effects in cardiovascular diseases
Why resveratrol and cardiovascular diseases? From a medical standpoint, CVDs are currently 
the first cause of death according to WHO. So much so, that RSV has been proposed as a pos-
sible treatment for prevalent CVD in relation to all the possible cardioprotective effects that 
have been uprising due to its extensive research [71].
3.1. From preclinical to clinical pharmacokinetics
Most of the extensive research so far has mainly been preclinical, both in vitro and in animal 
models as seen before. Preclinical studies are certainly a primary fundamental approach to 
identifying RSV potential direct and indirect molecular targets, mechanisms, and effects. 
These studies, in fact, give us a preview of the possible pharmacodynamics of RSV. This, 
however, neglects the main obstacle of all clinical research when introducing in the human 
body any kind of external element, pharmacokinetics. By this, I mean absorption, distribu-
tion, metabolism, and excretion. Research so far is not abundant and is mainly done on a 
restricted number of individuals. Moreover, studies initially focused on total plasma and 
urine RSV content due to lack of suitable metabolites standards of identification and quan-
tification. In the last years, the increased knowledge on RSV-derived metabolites in plasma 
and urine [72, 73], in particular trans-, cis- forms, mono- and di-glucuronides/sulfates and 
sulfoglucuronides, as well as dihydro-RSV (DHRSV), derived from microbiota metabolism 
[73, 74] has opened a new frontier on the true difference between these metabolites and their 
activity level [75]. Let us now take a direct view of the main human studies published on RSV 
pharmacokinetics:
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3.2. Absorption
After oral administration, the RSV plasma peak is reached in 30–60 min. In a clinical study 
in healthy volunteers, the absorption after oral administration of 25 mg of RSV was 70%, 
the peak plasma concentration of 491 ng/ml, and the plasma half-life of 9.2 h [74]. Systemic 
exposure to RSV (concentration-time curve) and peak plasma concentration were decreased 
(by 46 and 45%, respectively) when RSV (2 g twice daily) was administered with high-fat 
foods [76].
Interestingly, a six-daily 4-h interval (25, 50, 100, or 150 mg) RSV intake for 13 days on 20 
healthy males and 20 healthy females showed that area under curve values was not directly 
proportional to RSV intake, and that there is a high interindividual variability and that bio-
availability was higher after morning administration [77]. Another clinical study showed that 
bioavailability from wine and grape juice was around six times higher than that from tablets, 
in 11 healthy males consequent to either a single 250 ml red wine, 10 tablets, or 1 L grape 
juice intake with a 0.014 mg/kg of average RSV dose. Furthermore, a similar study with 10 
healthy men with single ingestion of 375 mL of red wine (6.3 mg total REA content) or 10 
capsules containing grape extract (total RSV content of 4.7 mg RSV) showed that grape extract 
RSV absorption was delayed versus red wine and moreover remained longer in the organism 
yielding higher RSV-derived metabolites [73].
RSV absorption studies have been performed on animals (mouse, rat) and using human liver 
cells (hepatocytes) and human tumor cells (colon carcinoma). The RSV contained in red wine 
is mainly present in the glycosylated trans- and cis-form (The two trans and cis spatial con-
formations are due to the presence of the double bond between the two phenolic rings.) The 
glycosidase RSV can be hydrolyzed from intestinal glucosidases to trans- and cis-RSV. In rats, 
it has been shown that RSV is absorbed in the intestine in a conjugated form with glucuronic 
acid [78].
It is estimated that in humans, 75% of the RSV administered orally is absorbed by the oral and 
intestinal mucosa and that the latter occurs mainly by trans-epithelial diffusion [79]. However, 
bioavailability is very low (<1%) and this could be due to rapid and intense metabolism and/
or by the capture of specific tissues (the liver would seem to be able to eliminate most of the 
RSV from the circulatory stream) [79]. The low bioavailability of RSV is associated with a low 
solubility in water (<1 mg/ml) [80]. Furthermore, trans-RSV is photosensitive, easily oxidized 
and with an unfavorable pharmacokinetic profile [81]. With daily feeding, free concentrations 
of RSV compatible with those that determine its biological actions in vitro (5–100 μmol) are 
not achieved in the target tissues nor can high doses of pure RSV be administered due to 
potential undesirable effects and drug interactions.
3.3. Distribution
RSV is distributed in the liver, to which it shows a high affinity, and in the kidneys and, to a 
lesser extent in the brain, heart, lungs, and testes (pharmacokinetic studies with C14-labeled 
trans-RSV) [82, 83]. RSV accumulates in conjugated, glucuronide, or sulfated forms in rat 
liver. Furthermore, a 12-h pharmacokinetic steady-state of RSV has been shown in a 2g RSV 
twice a day intake with standard breakfast and high-fat breakfast in a sample of five healthy 
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females and three healthy males [76]. Another interesting clinical trial on nine healthy males 
with single intake of 500 mL low-fat milk containing RSV (RSV dose 85.5 mg/70 kg) showed a 
high binding affinity of RSV glucuronide metabolites to plasma proteins [72].
3.4. Metabolism
RSV is metabolized by (1) sulfation (in the bowel/liver: limiting factor), (2) glucuronidation of 
the phenolic group, and (3) hydrogenation of the aliphatic double bond (intestinal microflora). 
Metabolic studies have shown that the most common metabolites of RSV are the derivatives 
conjugated with glucuronic acid (glucuronides) and sulfates, synthesized both in the liver 
and in the bowel. Moreover, RSV metabolism by human gut microbiota seems to have a pro-
nounced interindividual difference as shown in a study on 12 healthy volunteers with a single 
oral dose of 0.5 mg RSV/kg body weight in the form of grapevine-shoot supplement [84]. In a 
study, in healthy volunteers treated with RSV doses of 0.5–2.5 g, the most abundant metabo-
lite was found to be a monosulfate derivative, RSV-3-sulphate. In the blood, the concentration 
of RSV 3-sulfate and of the two monoglucuronide derivatives is about 20 times that of RSV; 
the same ratio is present when we compare the concentration-time curve (AUC) of the RSV 
with that of the RSV-3-sulfate (the AUC of the sulfate is about 18–23 times that of the RSV, 
while the AUC of the two glucuronides is 4–6 times that of RSV) [85]. Moreover, in another 
clinical trial, no gender or age-dependent differences were observed in RSV metabolic profile 
in a small sample healthy subjects distributed in six young and six elderly females and six 
young and six elderly males [86].
3.5. Excretion
The apparent clearance and mean volume of distribution of RSV are consistent with the low 
bioavailability of stilbene. The plasma half-life of RSV is between 2.9 and 8.9 h, similar to that 
of the two glucuronide derivatives (2.9–10.6 h) and the 3-sulfate derivative (3.2–11.5 h) [85].
4. Trying to make order on CV risk factors in human resveratrol 
trials
4.1. Hypertension
In the fight against cardiovascular diseases, control of arterial hypertension is what is giving 
the best results in terms of cost-effectiveness. The large pharmacological intervention studies 
have shown that the reduction of just 10% of the pressure values resulted in a 40% reduction 
in mortality from cerebrovascular accidents and 16–20% in mortality from coronary accidents. 
However, criteria must be followed to set up a rational and adequate treatment to bring the 
values of blood pressure back to norm or as close as possible to the norm. The first criterion 
must be based on the degree of hypertension, mild, moderate, or severe which, even if it has 
a purely indicative value, appears to be extremely useful on the clinical-therapeutic level. In 
fact, in the patient with mild hypertension, a sufficiently protracted period of controlled clini-
cal observation, up to 4–5 months, is necessary before starting a therapy, since the pressure 
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could fall within the normal values either spontaneously or with simple hygienic-dietetic 
measures. Moreover, in mild hypertension, it is advisable to start with a “light” drug therapy, 
in monotherapy, since the blood pressure control is often easy and the risk of complications 
is projected far in time and is, however, low. In case of moderate or severe hypertension, on 
the other hand, there is no longer any doubt as to the appropriateness of immediate phar-
macological treatment. In this case, the patient will be initiated to the therapy that must be 
undertaken gradually and continuously, besides a “step-up,” a “step-down” or a “side-step” 
therapeutical approach. Another criterion used for the purposes of the therapeutic approach 
is that which is based on the presence or absence of an organ damage, i.e., on the conse-
quences of hypertension. It is evident that the treatment of hypertension that has already 
caused heart failure, cerebrovascular accidents, or renal failure possesses much more difficult 
problems than hypertension without obvious complications and requires a considerable com-
mitment on the part of the doctor. A third criterion is that of the presence of concomitant 
pathologies on which some antihypertensive drugs can negatively interfere or whose treat-
ment can negatively interact with that of hypertension. Fortunately, the vast majority of cases 
of hypertension are represented as already mentioned by the mild and uncomplicated form 
so the problem of how to set up the therapy is not so crucial and basically identifies with the 
problem of choosing the drug or drugs more suitable. The choice of antihypertensive drug 
is, in fact, still today substantially empirical. In fact, we do not have criteria that allow us to 
make rational therapeutic choices, that is to say, based on the physiopathological character-
istics of the hypertensive state. At most, we can rely on some clinical data, which have some 
connection with the pathophysiology, but which are not strictly physiopathological. In this 
hypertension overview, it is important to understand where RSVs place lays. On a pure clini-
cal logical standpoint, RSV could be of great use in two main occasions: first, in borderline 
hypertension in which drugs have shown to have a degree of adverse effects and so we have 
this time span in which we, as of today, have no other treatment if not a dietary one and 
second, it could be a great ally in all degrees of hypertension in association with the standard 
FDA recommended drugs.
Let us see, however, if this perspective view is backed by clinical trial evidence.
As already specified before, clinical trials today are not sufficient to give a definite all-around 
answer, but the evidence today at hand is comforting. In fact, a randomized, crossover, 
double-blind, single-dose, placebo-uncontrolled clinical trial with a single ingestion of 30, 
90, 270 mg of synthetic RSV or placebo at weekly intervals, with analyses performed 1 h after 
consumption on nine healthy over-weighted/obese men or postmenopausal women with 
mildly elevated blood pressure, showed an acute RSV effect on FMD, which improved by 65% 
after consumption of 30 or 90 mg RSV and by 88% with 270 mg [87]. Another double-blind, 
randomized, placebo-controlled, crossover clinical trial on 18 patients with 330 mg of grape 
seeds and skin, 100 mg of green tea, 60 mg of RSV, 60 mg blend of quercetin and ginkgo biloba 
and bilberry on a 28 day basis showed a significant reduction in diastolic blood pressure 
[88]. RSV’s main purpose has been studied by this clinical crossover, randomized, double-
blind, placebo-controlled, single-center trial, which confirmed that RSV for 4 weeks lowers 
BP in prehypertensive and stage 1-hypertensive patients [89]. Another interesting study justi-
fies the idea of RSV acting in cohort with standard drugs; in fact, monitoring BP in patients 
with hypertension (BP prior to and following standard antihypertensive treatment plus RSV, 
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compared with a control group receiving standard antihypertensive treatment alone) showed 
that diastolic BP and systolic BP were significantly reduced with the addition of RSV to stan-
dard therapy [90] (Table 1). Despite great hopes, these studies are still insufficient for RSV 
recommendation in hypertension as more and better-performed trials must be done in terms 
of higher sample size and longer follow-ups, without forgetting the pharmacokinetic issue.
4.2. Atherosclerosis
Although atherosclerosis is a slowly progressive disease, at the same time it can be extremely 
dangerous, considering the risk of its evolution in heart attacks and strokes. Prevention is 
the best cure: we have seen that obesity is one of the predisposing factors for atherosclerosis; 
therefore, it is recommended to follow a low-calorie diet, to reduce weight and to practice 
constant exercise. For the same reason, patients suffering from atherosclerosis or otherwise 
at risk should stop smoking; hypertensives should constantly monitor blood pressure values 
to avoid very high peaks, which, as analyzed, can predispose the subject to atherosclerosis 
and its complications. For similar discourse for patients with high cholesterol, it is recom-
mended to undergo regular blood tests and follow a low-fat diet of lipids, to ensure the body 
a fair level of cholesterol in the blood. All these risk factors have in common the increased 
inflammatory state and lipid levels, which lead to mechanical and metabolic damage of the 
endothelial cells and deposit of lipidic and fibrotic matrix.
According to this, it is clear that an intervention on risk factors and behavioral habits can 
often block the cascade of events that would inevitably lead to the formation of atheroma. 
Sample population Dose Duration Effects Reference
Hypertension
19 healthy over-
weighted/obese men or 
postmenopausal women 
with mildly elevated blood 
pressure
30, 90, 270 mg of 
synthetic RSV or 
placebo at weekly 
intervals or placebo
Analyses 
performed 1 h after 
consumption
FMD improved by 65% 
after consumption of 30 
or 90 mg RSV and by 
88% with 270 mg
[87]
18 patients 330 mg of grape seed 
and skin, 100 mg of 
green tea, 60 mg of 
RSV, 60 mg of blend 
of quercetin and 
ginkgo biloba and 
bilberry or placebo
28 days Significant reduction in 
diastolic blood pressure
[88]
50 participants with 
prehypertension and 50 
participants with stage 1 
hypertension
500 mg of capsules, 
twice daily or 
placebo
4 weeks 
treatment–4 weeks 
washout–4 weeks 
treatment
Reduction in blood 
pressure
[89]
46 stage I hypertension and 
51, stage II hypertension 
patients
Evelor or placebo 6 months Diastolic BP and systolic 
BP were significantly 
reduced with the 
addition of RSV to the 
standard therapy
[90]
Table 1. Summary of clinical effects of resveratrol in hypertension.
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Atherosclerosis is now a treatable disease: compliance with certain behavioral rules, preven-
tion of risk factors and, possibly, the administration of specific drugs can not only block the 
degeneration of the disease but also and above all favor its regression.
In this sense, it is interesting to highlight the few clinical trials that invest in RSV and its role 
on atherosclerosis and on its two main components: oxidative stress and lipid profile.
A randomized, placebo-controlled 40 mg RSV capsule daily for 6 weeks on 20 healthy adults 
showed that RSV’s cellular activity has a direct influence on plasma biomarkers associated 
with inflammation and risk of various diseases, in terms of reduction in reactive oxygen 
species generation, p47 and intranuclear nuclear factor-kappaB binding, jun-N-terminal 
kinase-1, inhibitor of kappaB-kinase-beta, phosphor-tyrosine phosphatase-1B expression, 
and cytokine signaling-3 suppression in mononuclear cells when compared with the baseline 
and the placebo. PCE intake also suppressed plasma concentrations of TNF-alpha, IL-6, and 
C-reactive protein [91]. On the same false line, a crossover, placebo-controlled trial with a 
high-fat high-carbohydrate meal with placebo or 100 mg of RSV and 75 mg of grape skin 
polyphenol on a small sample of four healthy male and six healthy women showed an 
increase in Nrf-2 binding activity following the meal and increased mRNA expression of 
NQO-1 and GST-π1 genes and attenuated postprandial rise in CD14 and IL-1β mRNA and 
TLR4 protein in mononuclear cells, and a decreased plasma endotoxin concentration, thus 
demonstrating an acute reduction in postprandial inflammatory state [92]. A more straight-
forward study on the possible use of RSV in primary lone prevention of atherosclerosis done 
on a sample of 44 healthy subjects in a 1 month time period with a double-blind, randomized, 
placebo-controlled administration of 400 mg of trans-RSV, 400 mg of grape skin extract, and 
100 mg of quercetin showed a decreased expression of endothelial cell ICAM, VCAM, and 
IL-8 as well as a decreased level of plasma IFN-γ and insulin [93]. Other two straightfor-
ward studies instead tried to study the possible use of RSV in combination with standard 
atherosclerosis treatment. In the first, 75 patients on statins treatment at high CVD risk on 
a three-parallel arm, randomized, triple-blind, placebo-controlled trial on a 6-month daily 
ingestion of 350 mg placebo (n = 25), RSV containing grape extract (GE-RSV, grape phenolics 
+8 mg RSV, n = 25) or conventional grape extract lacking RSV (GE) showed a decrease in 
ApoB (−9.8%) and LDLox (−20%) in RSV-treated patients, beyond their treatment according 
to standard guidelines for primary prevention of CVD. In the second, with the same cohort as 
the first but on a 12-month daily ingestion of 350 mg placebo (n = 25), RSV containing grape 
extract (GE-RSV, grape phenolics +8 mg RSV, n = 25) or conventional grape extract lacking 
RSV (GE) for 6 months and the double dose for the following 6 months showed a GE-RSV 
nutraceutical decreased hsCRP (−26%), TNF (−19.8%), PAI-1 (−16.8%), and IL-6/IL-10 ratio 
(−24%), and increased IL-10 (19.8%). Furthermore, both studies showed no drug interactions 
or adverse effects [94, 95].
Worth mentioning is a study on healthy smokers, as we said before, smoking is not only 
an atherosclerosis risk factor but an overall CVD risk factor. In particular, randomized, 
double-blind, crossover trial on 50 healthy adult smokers, which were allocated to either 
“RSV-first” group (30 days of 500 mg RSV/day, 30 days washout, 30-day placebo) or to 
“placebo-first” group (30-day placebo, 30 days washout, 30 days of 500 mg RSV/day) 
showed a significant CRP and triglyceride concentrations reduction and increased total 
antioxidant status values [96] (Table 2).
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Sample 
population
Dose Duration Effects Reference
Atherosclerosis
20 healthy 
adults
40 mg of RSV capsule 
daily or placebo
6 weeks Reduction in reactive oxygen species 
generation, p47 and intranuclear 
nuclear factor-kappaB binding, 
jun-N-terminal kinase-1, inhibitor 
of kappaB-kinase-beta, phosphor-
tyrosine phosphatase-1B expression, 
and cytokine signaling-3 suppression 
in mononuclear cells when compared 
with the baseline and the placebo
[91]
Four healthy 
male and six 
healthy women
100 mg of RSV and 
75 mg of grape skin 
polyphenol or placebo
1, 3, and 5 hours 
after meal intake
Acute reduction in postprandial 
inflammatory state
[92]
44 healthy 
subjects
400 mg of trans-RSV, 
400 mg of grape skin 
extract and 100 mg of 
quercetin or placebo
1 month Decreased expression of endothelial 
cell ICAM, VCAM and IL-8 as well 
as a decreased level of plasma IFN-γ 
and insulin
[93]
75 patients 
on statins 
treatment at 
high CVD risk
RSV-containing grape 
extract (GE-RSV, grape 
phenolics +8 mg RSV) 
or conventional grape 
extract lacking RSV (GE) 
or placebo
6 months Decrease in ApoB (−9.8%) and LDLox 
(−20%) in RSV-treated patients
[94]
75 patients 
on statins 
treatment at 
high CVD risk
RSV-containing grape 
extract (GE-RSV, grape 
phenolics +8 mg RSV) 
or conventional grape 
extract lacking RSV (GE) 
or placebo
6 months + 
double dose for 
the following 
6 months
Decreased hsCRP (−26%), TNF 
(−19.8%), PAI-1 (−16.8%) and IL-6/
IL-10 ratio (−24%), and increased 
IL-10 (19.8%)
[95]
50 healthy adult 
smokers
500 mg of RSV/day or 
placebo
30 days of 500 mg 
RSV/day (or 
placebo), 30 days 
washout, 30-days 
of 500 mg RSV/
day (or placebo)
Significant CRP and triglyceride 
concentrations reduction, and 
increased total antioxidant status 
values
[96]
Table 2. Summary of clinical effects of resveratrol in atherosclerosis.
These trials took together, although still insufficient as evidence, give us a broad perspec-
tive on RSV use in atherosclerosis. RSV supplementation due to its anti-inflammatory, anti-
oxidant, and hypotriglyceridemic effects, it is beneficial to those with increased CVD risk 
factors, both high and low, such as smokers and as a lone primary prevention therapy as 
well as in association therapy. Even if repetitive, more and better-performed trials must be 
done in terms of higher sample size and longer follow-ups in order to recommend RSV as an 
atherosclerosis therapy.
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4.3. Heart diseases
Heart disease is the leading cause of death for men and women of all racial groups and affects 
all population ages, thus representing the leading cause of death in industrialized countries. 
Among these, coronary artery disease (CAD) is the most common condition associated with 
high mortality and morbidity. Clinical manifestations of ischemic heart disease include silent 
ischemia, stable and unstable angina pectoris, myocardial infarction (MI), heart failure, and 
sudden death. It has been widely ascertained that acute coronary syndromes in their various 
forms of presentation share a common pathophysiological mechanism, such as the rupture 
or erosion of the atherosclerotic plaque (of which we have already mentioned the uses of the 
RSV), on which phenomena overlap thrombotic and embolism at the distal level, as well as 
pro-inflammatory state and endothelial dysfunction.
In these terms, we understand the importance of preventing diseases which once again, for 
the umpteenth time, can only be done by prevention of heart disease that expresses the only 
winning weapon. Depending on the general health of the patient, it may be necessary to 
administer drugs for the heart, for obesity, for hypertension, and for hypercholesterolemia, as 
well as to follow a healthy and balanced diet, without excess exercise constantly. In this con-
text, we try to understand through the various trials available to us how the administration of 
RSV can also act on the heart component directly without forgetting the already-mentioned 
beneficial effects associated.
In 40 stable CAD patients, a randomized, two-parallel arm, double-blind, placebo-controlled 
trial with a 3-month daily ingestion of 10 mg RSV in one of the groups showed that RSV 
decreased, versus baseline, LDL (8%) and improved endothelial function (50%), left ven-
tricular diastolic function (2%), and protected from unfavorable hemorheologic changes. 
This highlights the RSV’s cardioprotective effects after myocardial infarction [97]. Another 
interesting trial in 116 patients with stable angina pectoris in a randomized, double-blind, 
active-controlled, and parallel trial with three groups of subjects who received the test drugs 
and one control group of subjects who were not randomized with inclusion, 30 and 60 days 
of oral supplementation with calcium fructoborate (CF) (112 mg/day), RSV (20 mg/day), and 
their combination showed a significant hs-CRP decrease in all groups at the 30- and 60-day 
visits: 39.7% at 60 days for the CF group and 30.3% RSV plus CF at 60 days. The N-terminal 
prohormone of BNP was significantly lowered by RSV (59.7% at 60 days) and by CF (52.6% 
at 60 days). However, their combination was the most effective and induced a decrease of 
65.5%. Lipid markers showed slight changes from baseline in all groups. Overall, this study 
confirmed the anti-inflammatory and lipid effect of RSV and introduces RSVs effect on left 
ventricle function enhancement, or more correctly recover, as shown by N-BNP marker 
[98]. Last but not the least, in 75 patients with stable CAD in a three-parallel arm, random-
ized, triple-blind, dose-response, placebo-controlled trial with a 12-month daily ingestion of 
350 mg placebo (n = 25), RSV-containing grape extract (GE-RSV, grape phenolics +8 mg RSV, 
n = 25) or conventional grape extract lacking RSV (GE) for 6 months and the double dose for 
the following 6 months showed a significant increase in adiponectin levels (10%) in GE-RSV 
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group in addition to a decrease in PAI-1 levels, non-HDL cholesterol decreased significantly 
in both GE and GE-RSV groups, and downregulation of pro-inflammatory genes expression 
in PBMCs isolated from GE-RSV group patients. This highlights RSV’s possible fibrinolytic 
effect on such patients confirming its overall anti-inflammatory effect in patients with estab-
lished disease as did the two trials before [75].
Looking at these three trials and their results, the main suggestion would be to use RSV as an 
enhancement to the therapies now at our disposal for patients with previous cardiovascular 
accidents as it has shown not only to be of great importance for prevention of heart diseases 
through its anti-inflammatory and lipid profile effects but it also seems as it can modify left 
ventricle function (Table 3). Of course, three trials are away from sufficient to make such sug-
gestion an indication, as so much has still to be done.
4.4. Diabetes type 2
Diabetes care is a very complex and articulated. The therapeutic objective is the same for any type 
of diabetes and consists in taking down high levels of blood glucose within the normal blood 
glucose values. This objective is more than anything else from a real need since hyperglycemia 
Sample 
population
Dose Duration Effects Reference
Heart diseases
40 stable 
CAD patients
Daily ingestion of 10 mg 
RSV or placebo
3 months Decreased LDL (8%) and improved 
endothelial function (50%), left ventricular 
diastolic function (2%) and protected from 
unfavorable hemorheologic changes versus 
baseline
[97]
116 patients 
with stable 
angina 
pectoris
Calcium fructoborate 
(CF) (112 mg/day), RSV 
(20 mg/day), and their 
combination or placebo
30 and 60 days Significant hs-CRP decrease in all groups 
at the 30-day and 60-day visits: 39.7% at 
60 days for the CF group and 30.3% at 
60 days for RSV plus CF. The N-terminal 
prohormone of BNP was significantly 
lowered by RSV (59.7% at 60 days) and 
by CF (52.6% at 60 days). However, their 
combination was the most effective and 
induced a decrease of 65.5%. Lipid markers 
showed slight changes from baseline in all 
groups. Overall, this study confirmed the 
anti-inflammatory and lipid effect of RSV 
and introduces RSVs effect on left ventricle 
function enhancement, or more correctly 
recover, as shown by N-BNP marker
[98]
75 patients 
with stable 
CAD
RSV-containing grape 
extract (GE-RSV, grape 
phenolics +8 mg RSV) 
or conventional grape 
extract lacking RSV 
(GE) or placebo
6 months 
+ double 
dose for the 
following 
6 months
Increase in adiponectin levels (10%) in 
GE-RSV group in addition to a decrease 
in PAI-1 levels, non-HDL cholesterol 
decreased significantly in both GE and 
GE-RSV groups and downregulation 
of pro-inflammatory genes expression 
in PBMCs isolated from GE-RSV group 
patients
[75]
Table 3. Summary of clinical effects of resveratrol in heart diseases.
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depends not only on the symptoms but also on acute and long-term complications of diabetes 
mellitus. Therefore, treatments that allow the achievement of the aforementioned objective 
deserve a quote: the adoption of a healthy and balanced diet, the regular practice of exercise 
and the intake of specific drugs for the reduction of blood sugar. Finally, concluding this rapid 
overview of diabetes therapy, it is important to note the importance of the regular monitoring 
of the effectiveness of the treatments adopted. This aspect is important because it allows the 
attending physician to understand if the therapy in place is working or not.
In this view, RSV can play an important role, let us see the understandings of few trials at 
our disposal. In 19 type 2 diabetics, a two-parallel arm, randomized, double-blind, placebo-
controlled trial with a daily ingestion of 10 mg RSV for 4 weeks (n = 10 or placebo, n = 9) 
showed a decrease in insulin resistance possibly due to a decrease in oxidative stress and 
improvement of insulin signaling via the Akt pathway [99]. In another study, 62 type 2 
diabetics in a randomized, two- parallel arm, placebo uncontrolled, unblinded trial with a 
3-month daily ingestion of hypoglycemic drugs +250 mg RSV (n = 28) or only hypoglyce-
mic drugs in control group (n = 29) showed that RSV improved systolic and diastolic blood 
pressures, HbA1c (−5%), total cholesterol, and LDLc concentrations [100]. On the same line, 
another interesting study on 66 type 2 diabetics in a randomized placebo-controlled, double-
blind, parallel clinical trial supplemented with 1 g/day of RSV for 45 days showed significant 
decrease in systolic blood pressure, fasting blood glucose, hemoglobin A1c, insulin, and 
insulin resistance, while HDL was significantly increased, when compared to their baseline 
levels [101].
These studies considered as a whole show that RSV has many important antidiabetic effects 
as it improves insulin sensitivity, glycemic control, and also acts on associated risk factors 
such as inflammation and lipid profile (Table 4). Overall, RSV seems to have all the main 
specifics for the perfect antidiabetic drug. Although, as expected, more trials are needed 
since the observed reductions in HbA1c and HDL with RSV supplementation are so signifi-
cant, compared to the benefits achieved with frontline antidiabetic drugs; we can hope for 
the best.
Sample 
population
Dose Duration Effects Reference
Type 2 diabetes
19 type 2 
diabetics
Daily ingestion of 10 mg 
of RSV or placebo
4 weeks Decrease in insulin resistance possibly 
due to a decrease in oxidative stress and 
improvement of insulin signaling via the 
Akt pathway
[99]
62 type 2 
diabetics
Hypoglycemic drugs 
+250 mg RSV(or placebo)
3 months Improved systolic and diastolic blood 
pressures, HbA1c (−5%), total cholesterol, 
and LDLc concentrations
[100]
66 type 2 
diabetics
1 g/day of RSV or 
placebo
45 days Decrease in systolic blood pressure, fasting 
blood glucose, hemoglobin A1c, insulin, 
and insulin resistance, while HDL was 
significantly increased, when compared to 
their baseline levels
[101]
Table 4. Summary of clinical effects of resveratrol in type 2 diabetes.
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5. Effects of resveratrol in cerebrovascular diseases
The most frequent cause of death in the western world, after heart disease and cancer, is 
cerebrovascular disease and is the second most common cause of neurological disability, after 
Alzheimer’s disease [102]. It has been found that half of the patients with neurological dis-
eases also present cerebrovascular diseases. The term cerebrovascular disease indicates any 
cerebral alteration resulting from a pathological process affecting the blood vessels, whether 
they are arteries, arterioles, capillaries, veins, or venous sinuses (venous sinus). The vascular 
lesion may have anatomopathological characteristics of an occlusion by a thrombus or an 
embolus, or a rupture; the consequences at the level of the cerebral parenchyma are of two 
types: ischemia (with or without infarction) and hemorrhage. An alteration of the vessel wall 
permeability, hypertension, and increase in blood viscosity or modifications of another rheo-
logical characteristic are other pathophysiological mechanisms involved in cerebrovascular 
pathology.
The most common presentations of cerebrovascular diseases are stroke and transient ischemic 
attack (TIA). Stroke is caused by cerebral ischemia, that is the interrup-tion of the blood flow 
to the brain, of the duration enough to determine the appearance of focal signs and symptoms 
that do not disappear within 24 h, while, TIA consists in a sudden appearance of focal signs 
and symptoms, attributable to transient cerebral ischemia, which disappear within 24 h.
Most cerebrovascular diseases depend on atherosclerosis and arterial hypertension, and the 
main forms are characterized by cerebral insufficiency caused by transient disturbances of the 
blood flow. Moreover, diseases such as diabetes and atherosclerosis can be complicated by 
hypertension and increase the viscosity of the blood, without forgetting the important role of 
aging. In fact, an altered vascular permeability is responsible for headache, cerebral edema, 
and seizures of hypertensive encephalopathy. Signs and symptoms of cerebrovascular dis-
eases reflect the damaged brain areas and not necessarily the affected artery.
The main causes are the formation of atherosclerotic plaques at the level of the carotids, embo-
lisms from the heart, hematological disorders, fibromuscular dysplasia, and vasculitis, i.e., 
inflammatory processes in the blood vessels that cause the lumen to shrink [102].
5.1. Resveratrol in cerebrovascular diseases
Neurodegenerative diseases share common features such as chronic vascular damage due to 
oxidative stress and inflammation damage, which underline neural damage and thus neuro-
nal death. Taking into account the mechanisms associated with vascular damage, let us see the 
role of RSV. As already mentioned, RSV has been shown through great preclinical evidence to 
have strong anti-inflammatory properties, as well as many antioxidant capacities, apoptosis 
inhibition, multiple transcriptional signaling pathways, and direct neurological function. As 
many works show, RSV inflammatory-response inhibition in the nervous system is mainly 
due to a reduction in TNFα, iNOS, COX-2, IL-1α, IL-1β, MMP-9, and p-p53, all inflammatory 
markers of great neural importance [103]. Reduction in oxidative stress is mainly mediated 
by an increase in eNOS, NO, SOD, GPx1, CAT, HO-1 levels accompanied by a decrease in 
MPO and ROS. Other important oxidative stress mechanisms include an increase in GSH, 
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VEGF, Trx-2, and mitochondrial biogenesis, while a reduction in XO and MDA. RSV apop-
tosis inhibition function is associated with a reduction in caspase-3, caspase-7, CYT-c, and 
Bax with increased Bcl-2. Finally, RSV’s direct neuroprotective properties can be identified 
in the reduction of neurological deficit score and β-amyloid peptide with a contemporary 
increase in neuron survival, motor function and in TH, dopamine, and AchE levels. Main sig-
naling pathways, protein kinase, and transcriptional factor modulators include Nrf-2, NFκB, 
p38MAPK, PGC-1 h, PI3K/Akt, mTOR, PPAR, AMPK, CREB, PKC, and SIRT [104–109].
5.2. Clinical trials on resveratrol effects in cerebrovascular diseases
Although RSV’s neurological properties are many, the study of the pathologies of the nervous 
system is still very complex due to the missing knowledge in the exact mechanisms, so we can 
only depend on biomarkers of the single pathologies.
As far cerebrovascular diseases are considered, two are the main works at our disposal. The 
first work, on 4 young healthy men and 20 women in a double-blind, placebo-controlled, 
crossover with a single or once daily on 3 separate days with 250 or 500 mg of RSV, showed 
that RSV increased cerebral blood flow and hemoglobin but did not enhance cognitive func-
tion. Interestingly, the blood flow increase was dose dependent [110]. The second work evalu-
ated if RSV use in coadministration with r-tPA for brain ischemic stroke treatment is more 
effective than r-tPA alone. These 312 patients were randomly divided according to their onset-
to-treatment time (OTT) (early OTT or delayed OTT); afterward they were either treated with 
the association of r-tPA and placebo or with r-tPA plus RSV. Patients receiving delayed OTT 
r-tPA plus RSV treatment showed a reduction in matrix metalloproteinase (MMP)-2 and 
MMP-9 plasma levels; moreover, reductions in both MMPs and patient NIHSS scores were 
observed [111].
These two trials show a positive effect of RSV in cerebrovascular diseases both in a possible 
chronic use as seen by the increase in the cerebral blood flow and in an acute state for its 
positive effects in coadministration with r-tPA. Overall, it is almost impossible to evaluate 
RSV use in specific cerebrovascular diseases; as of now its use in stroke is the only plausible 
prospective indication. Of course, the way is still long and both preclinical and clinical trials 
are needed.
As far as neurodegenerative disease go, at our disposal, there are only two clinical trials both 
on Alzheimer disease (AD). These two studies were conducted on similar cohorts of 119 
patients in a randomized, placebo-controlled, double-blind, multisiter, phase 2 trial manner. 
In both, 500 mg was administered once daily, with 500 mg dose escalation every 13 weeks, 
ending with 1000 mg of administration twice daily for 12 months, which, however, found 
different understandings. The first study showed a reduced CSF MMP9, increased IL-4, and 
attenuated decline in Aβ42 and Aβ40, while the second showed the same attenuation in Aβ42 
and Aβ40 accompanied by increased brain volume loss [112, 113] (Table 5).
Overall, these two studies are useful to conclude that RSV metabolites penetrate the blood-
brain barrier and have effects on the central nervous system, and these effects are mainly asso-
ciated with an anti-inflammatory and antineurodegenerative effect. Collectively, we could 
assess that there is a place for RSV in neurodegenerative disease treatment; however, we are 
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still to understand which viable targets RSV focuses on which could be the biomarkers useful 
to understand RSV activity and effectiveness. As for as cerebrovascular disease considered, 
here as well, much is to be done in both preclinical and clinical stages.
6. Conclusion
Prevention policies mainly invest in medical interventions, although it has been known for 
several years, that lifestyle changes, mainly focused on exercise and nutrition, can produce a 
significant reduction in cardiovascular risk, with antiatherosclerotic effects, antithrombotic, 
anti-ischemic, antiarrhythmic with a significant reduction in mortality and incidence of 
infarction. Dietary and physical activity changes, together with the improvement of body 
composition, give a sense of general well-being. On the contrary, pharmacological interven-
tions, together with their indispensable curative effect, unfortunately almost always present 
side effects that worsen the quality of life.
The presented data in this study have demonstrated the role of resveratrol in prevention of 
cardiovascular abnormalities induced by atherogenic diet. The overall data revealed that res-
veratrol possesses the cardioprotective effect by improving the serum lipid profile, antioxi-
dant system, improving lipid metabolism, and cardiac tissue damages either in myocardium 
and aorta.
Sample 
population
Dose Duration Effects Reference
Cerebrovascular diseases
Four young 
healthy men 
and 20 women
Single or once daily on three 
separate days 250 or 500 mg of 
RSV or placebo
After a 
45-min resting 
absorption 
period
Increased cerebral blood flow 
and hemoglobin but did not 
enhance cognitive function
[110]
312 brain 
ischemic 
stroke patients
r-tPA + placebo or with 
r-tPA + resveratrol
24 hours after 
the treatment, 
outcomes were 
assessed
Reduction in matrix 
metalloproteinase (MMP)-2 and 
MMP-9 plasma levels; moreover, 
reductions in both MMPs and 
patient NIHSS scores were 
observed
[111]
119 patients 500 mg once daily, with 
500 mg dose escalation 
every 13 weeks, ending 
with 1000 mg twice daily 
administration
12 months Reduced CSF MMP9, increased 
IL-4, and attenuated decline in 
Aβ42 and Aβ40
[112]
119 patients 500 mg once daily, with 
500 mg dose escalation 
every 13 weeks, ending 
with 1000 mg twice daily 
administration
12 months Attenuation in Aβ42 and Aβ40 
accompanied by increased brain 
volume loss
[113]
Table 5. Summary of clinical effects of resveratrol in cerebrovascular diseases.
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On the basis of the beneficial properties that resveratrol evoked on human health, the findings 
support a role for regular consumption of dietary resveratrol by consumption of resveratrol-
rich fruits or vegetables to avoid the risk of cardio- and cerebrovascular diseases, in order to 
add life to the years and not only years to life.
Acronyms and abbreviations
AMPK adenosine monophosphate-activated protein kinase
Bax Bcl-2-associated X protein
Bcl-2 B-cell lymphoma 2
CAT catalase
COX cyclooxygenase
CREB cAMP response element binding
Cyt-c cytochrome C
eNOS endothelial nitric oxide synthase
GPx glutathione peroxidase
GSH glutathione
HO-1 heme oxygenase-1
IL interleukin
iNOS inducible nitric oxide synthase
MAPKs mitogen-activated protein kinases
MDA malondialdehyde
MMP matrix metallopeptidase
MPO myeloperoxidase
mTOR mammalian target of rapamycin
NF-κB nuclear factor kappa B
NO nitric oxide
Nrf nuclear factor-E2-related factor
p53 tumor protein 53
PGC peroxisome proliferator-activated receptor-gamma coactivator
PI3K phosphoinositide 3-kinase
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PKC protein kinase C
PPAR peroxisome proliferator-activated receptor
ROS reactive oxygen species
RSV resveratrolo
SIRT1 sirtuin 1
SOD superoxide dismutase
TH tyrosine hydroxylase
TNFα tumor necrosis factor alpha
Trx thioredoxin
VEGF vascular endothelial growth factor
XO xanthine oxidase
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